Form 4: Alexander Denner Reports Changes in Ironwood Pharmaceuticals Ownership
SEC Form 4
Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership, including the acquisition of shares and indirect ownership through Sarissa Capital Management LP.
Summary
- Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On March 15, 2024, Denner acquired 1,662 shares of Class A Common Stock at $0 per share, issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy.
- Denner also indirectly owns 16,390,000 shares through Sarissa Capital Management LP and its associated funds.
- Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
- Sarissa Capital Management LP also filed a report regarding these holdings.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of shares by a director may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Effective date of the Second Amended and Restated Non-employee Director Compensation Policy |
| March 15, 2024 | Date of transaction where Alexander Denner acquired 1,662 shares of Class A Common Stock |
| March 19, 2024 | Date of signature for the report by Sarissa Capital Management LP and Alexander Denner |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.